On the FDA horizon: 6 peptides likely to land 2026-2028, and what each one changes

Updated 2026-05-02: three of the six compounds covered here moved before this post even settled. Orforglipron approved as Foundayo on April 1, 2026 under the FDA's National Priority Voucher program. Survodutide phase 3 obesity readout landed April 28, 2026 at 16.6%. TRIUMPH-4 was the obesity + knee OA cohort (28.7% weight loss at 12mg, December 2025), not the cardiovascular outcomes trial · TRIUMPH-3 is the CV outcomes trial and reads out 2027. The current snapshot lives at /blog/peptide-pulse-may-2026 · this piece stays as the original horizon framing for the longer-tail compounds (MariTide, CagriSema, retatrutide TRIUMPH-3, survodutide MASH).

The next two years are about to reshape what "best-in-class" means for weight management, glycemic control, and metabolic-liver disease. Six compounds are queueing for FDA decisions between mid-2026 and end-2028. Five are GLP-1-class incretins with a twist (a second receptor, a third receptor, an oral form, or a once-monthly form). One sits outside the incretin family entirely. All of them have phase 3 data on the public record or imminent.

This post is the horizon survey. What each compound is, where it sits in trials, the readout window, the mechanism advantage versus what's already on shelves, and what each approval would shift for routing decisions Panya is making today. Sources are public regulatory filings, sponsor investor calls, and peer-reviewed journal readouts where available.

A note on the rating column. Phase 3 efficacy and safety look strong on most of these, but a positive readout is not the same as an FDA decision, and an FDA decision is not the same as commercial supply. We are conservative on the timeline column for that reason. The science is bleeding edge; the routing posture stays cautious.

1. Retatrutide (Eli Lilly) · GLP-1 + GIP + glucagon triple agonist

Phase: 3 (TRIUMPH program). TRIUMPH-1 and TRIUMPH-2 readouts public; TRIUMPH-4 cardiovascular outcomes still in flight.

Readout window: TRIUMPH-4 primary efficacy late 2026 or early 2027. FDA filing late 2026; decision likely late 2027 absent a priority review.

Mechanism advantage: triple agonist. GLP-1 + GIP gives you tirzepatide; adding a glucagon-receptor agonist drives additional energy expenditure and hepatic-fat reduction. The 24.2% mean weight reduction at 12mg in TRIUMPH-1 puts retatrutide above tirzepatide on the same endpoint at the same timepoint by roughly 3 percentage points.

What it changes: above 22 to 24% weight reduction matters clinically · this is bariatric-surgery-adjacent territory without surgery. If TRIUMPH-4 reads out clean on cardiovascular endpoints, retatrutide becomes the new ceiling for the class. Expect the routing question on tirzepatide to shift from "is this enough" to "is the next-generation already close enough to wait."

Panya rating posture: hold on routing recommendations until FDA decision plus 6 months of commercial supply data. We have a dedicated retatrutide phase 3 update on the science.

2. Orforglipron (Eli Lilly) · oral small-molecule GLP-1 agonist

Phase: 3 (ACHIEVE and ATTAIN programs · ACHIEVE-1 in T2D, ATTAIN-1 in obesity). Phase 3 readouts in 2025 and early 2026.

Readout window: Lilly indicated FDA submission for obesity in 2025 with potential approval mid to late 2026. T2D submission was reported in 2025 with potential approval late 2026 or early 2027.

Mechanism advantage: not a peptide, despite the name · orforglipron is a small-molecule oral GLP-1 receptor agonist. No injection. No cold chain. No food restriction (unlike oral semaglutide / Rybelsus, which requires fasting and a small water volume). Manufacturing scales differently than peptide synthesis.

What it changes: this is the supply story. Injectable GLP-1 capacity has been the rate-limiting bottleneck on the entire class for three years. Small molecule manufacturing is faster, cheaper, geographically distributed across more contract manufacturers, and decouples from peptide synthesis capacity. Orforglipron approval would not necessarily be the highest-efficacy GLP-1 (phase 3 weight loss looked closer to semaglutide than tirzepatide) · it would be the first one that scales.

What it does not change: efficacy is not the headline. Phase 3 weight reduction landed roughly in the 14 to 15% band at the high doses · solid, comparable to semaglutide, below tirzepatide. If you are routing on maximum efficacy, orforglipron is not the answer. If you are routing on access and price, it might be.

Panya rating posture: watch for the FDA decision and the first 90 days of commercial pricing. If oral generics-cost trajectories play out the way most analysts expect, this changes the price floor for the entire GLP-1 class within 18 months of approval.

3. CagriSema (Novo Nordisk) · semaglutide + cagrilintide fixed-dose combo

Phase: 3 (REDEFINE program · REDEFINE-1 obesity, REDEFINE-2 T2D + obesity, REDEFINE-3 cardiovascular outcomes).

Readout window: REDEFINE-1 readout was December 2024 with a 22.7% weight reduction headline · below the pre-trial guidance of 25%, which knocked Novo's stock and reset expectations. REDEFINE-2 readout in 2025. FDA submission anticipated late 2025 or 2026; approval potentially 2026 to 2027.

Mechanism advantage: amylin analog (cagrilintide) co-administered with GLP-1 (semaglutide). Amylin agonism slows gastric emptying and reduces food intake via a different receptor pathway than GLP-1, theoretically additive. The combination is a single weekly injection, fixed-dose ratio.

What it changes: the most interesting question is whether amylin agonism produces a meaningfully different fat-versus-lean-mass loss profile compared to pure GLP-1. Animal and small human studies suggest amylin may preserve lean mass relatively better, which would matter for the post-50 cohort that loses lean mass more readily on semaglutide and tirzepatide. The human data is not yet definitive at scale.

What it does not change: REDEFINE-1 numbers were closer to tirzepatide than to retatrutide. CagriSema is a refinement, not a generational leap. Routing changes only if the lean-mass-preservation hypothesis confirms in the published trial data.

Panya rating posture: hold. The interesting routing case is the lean-mass-preservation question, and that requires DXA-based body-composition data which is not the primary endpoint in REDEFINE.

4. Survodutide (Boehringer Ingelheim and Zealand Pharma) · GLP-1 + glucagon dual agonist

Phase: 3 in obesity (SYNCHRONIZE program), phase 3 in MASH (LIVERAGE program), phase 2 in MASH cirrhosis.

Readout window: phase 2 MASH data published 2024 · 83% achieved at-least-30% relative reduction in liver fat at the high dose, 64.5% achieved MASH resolution without worsening fibrosis at 48 weeks. Phase 3 MASH readouts expected 2026 to 2027. Obesity phase 3 readout 2026.

Mechanism advantage: GLP-1 + glucagon dual (without GIP). Glucagon agonism drives hepatic-fat clearance directly, which is why the MASH numbers are striking · MASH is the indication where survodutide could land first regulatory approval, separately from weight management.

What it changes: if survodutide gets FDA approval for MASH ahead of resmetirom's market expansion, it becomes the first injectable peptide approved specifically for steatotic liver disease, with a side-effect of meaningful weight loss. Routing implications go beyond weight management · gastroenterology starts paying attention.

What it does not change: the obesity-only phase 2 readouts were strong but not generationally above tirzepatide. As a pure weight-management routing decision, survodutide is the second-best dual agonist.

Panya rating posture: the MASH indication is where this matters. Watch the phase 3 LIVERAGE readouts and the resmetirom commercial trajectory in parallel. We will publish a MASH-specific routing post once the LIVERAGE data lands.

5. MariTide (maridebart cafraglutide, Amgen) · GLP-1 receptor agonist + GIP receptor antagonist (monthly)

Phase: 3 (MARITIME program · two phase 3 obesity trials enrolling 2024 to 2025).

Readout window: MARITIME phase 3 readouts expected late 2026 to 2027. FDA submission likely 2027.

Mechanism advantage: this is the contrarian one. MariTide is a GLP-1 agonist plus a GIP receptor antagonist · the opposite GIP polarity to tirzepatide and retatrutide, which agonize GIP. Amgen's bet is that blocking GIP rather than activating it is the cleaner route to fat-mass reduction. Phase 2 readout in November 2024 showed roughly 20% weight reduction at 52 weeks at the high dose, with the headline feature being a once-monthly injection schedule rather than weekly.

What it changes: the dosing-schedule question. If MariTide approves with a once-monthly label and efficacy in the 18 to 22% band, the patient-experience advantage over weekly tirzepatide is real for cohorts that struggle with adherence. Once-monthly also changes supply-chain dynamics · 4x fewer dispensing events per patient per year.

What it does not change: the phase 2 weight-loss curve in the November 2024 readout did not show a clear plateau, which means the trial timeline is still answering whether 20% is the steady-state number or whether the dose-response curve continues. We do not know the cardiovascular safety story yet · MARITIME readouts will be the first large-cohort answer.

Panya rating posture: high uncertainty, high upside on the convenience axis. Hold on routing until phase 3 readouts.

6. Pemvidutide (Altimmune) · GLP-1 + glucagon dual agonist (MASH-focused)

Phase: 3 in MASH (IMPACT-MASH program), phase 2 obesity readout in 2024.

Readout window: IMPACT-MASH phase 2b readout was 2024 · 59.1% MASH resolution without worsening fibrosis at 24 weeks at the high dose. Phase 3 readout expected 2027. Obesity phase 3 enrolling 2025.

Mechanism advantage: another GLP-1 + glucagon dual, designed specifically with a higher glucagon-to-GLP-1 receptor ratio than survodutide · in theory more aggressive on hepatic-fat clearance, less aggressive on appetite suppression. The trade-off is that obesity weight-loss numbers in pemvidutide trials run lower than survodutide (10 to 15% range, not 20%+), but the MASH numbers are competitive.

What it changes: if FDA approves pemvidutide for MASH it becomes a single-indication (or MASH-primary) GLP-1-class drug, the first one where obesity is the secondary outcome rather than the headline. Routing question: for a MASH-positive patient who is mildly to moderately obese (BMI 30 to 35), is pemvidutide the better match than survodutide or tirzepatide because the indication is more specific? The data does not yet answer that.

Panya rating posture: hold. Smaller sponsor than the others on this list, which historically has meant more launch-supply turbulence than a Lilly or Novo launch. Watch the MASH-specific routing case if and when phase 3 IMPACT-MASH reads out clean.

What we are watching as gates

Each of these compounds clears two gates before it changes Panya's routing recommendations.

Gate 1: phase 3 efficacy + safety in the public record. Sponsor press releases are not the bar. Published peer-reviewed data or full FDA briefing documents are. Five of the six on this list have at least one phase 3 readout in the public record; orforglipron has the most, retatrutide the highest-profile.

Gate 2: FDA decision + 90 days of commercial supply data. "Approved" is necessary but not sufficient. Tirzepatide had 12 months of supply turbulence post-launch. Semaglutide had longer. Routing recommendations are downstream of "can the patient actually get this and pay for it" · until we see commercial supply behavior, the rating column says "watch", not "route."

The horizon is real and the science is moving faster than at any point in the GLP-1 era. We will update each of these as readouts land. The rating posture is conservative because the gap between "phase 3 worked" and "the patient can get the drug at a non-cash price" is where most launch cohorts get burned. Panya's posture is: cover the science early, route only after the supply has settled.

For the current routable cohort, see /vendor and the 11-signal rubric. For the live retatrutide deep-dive, see /blog/retatrutide-phase-3-update-2026.